Company / EPS (Basic)
Mineralys Therapeutics, Inc. EPS (Basic) History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$3.66
FY2024
5-year range
-$5.77 / -$1.99
FY2022-FY2024
Trend
-83.9%
vs FY2023
Sector context
#162 of 208
Health Care
What the data says
Mineralys Therapeutics, Inc.'s eps (basic) of $-3.66 is lower than 78% of companies in the Health Care sector (FY2024). Improved from $-5.77 to $-3.66 over the past 2 years.
Based on SEC 10-K filings.
-3.66 in FY2024.
Improved from $-5.77 to $-3.66 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 208This company -$3.66 Sector average -$0.87
▼
-320.4% below sector average
Key checks
Key Insights
- In FY2024, eps (basic) decreased 83.9% year-over-year.
- Ranks #162 out of 208 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$3.66 | -83.9% |
| FY2023 | -$1.99 | +65.5% |
| FY2022 | -$5.77 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026